Grace therapeutics, inc. GRCE.US Overview
GRCE AI Analysis & Strategy
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
GRCE Current Performance
-4.15%
Grace therapeutics, inc.
-1.01%
Avg of Sector
-0.79%
S&P500
GRCE Key Information
GRCE Financial Forecast
Unit : USD
GRCE Earnings Table
GRCE Profile
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Price of GRCE
GRCE FAQ
When is GRCE's latest earnings report released?
The most recent financial report for Grace therapeutics, inc. (GRCE) covers the period of 2025Q4 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GRCE’s short-term business performance and financial health. For the latest updates on GRCE’s earnings releases, visit this page regularly.
How much cash does GRCE have?
At the end of the period, Grace therapeutics, inc. (GRCE) held Total Cash and Cash Equivalents of 22.13M, accounting for 0.31 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is GRCE's EPS continuing to grow?
According to the past four quarterly reports, Grace therapeutics, inc. (GRCE)’s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.1. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of GRCE?
Grace therapeutics, inc. (GRCE)’s Free Cash Flow (FCF) for the period is -2.95M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 40.07% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.